You are here

Tigecycline In-Vitro Surveillance Study In Taiwan

Last updated on April 2, 2020

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Taipei, Taiwan, 100 China
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Community Acquired Infections
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Clinically relevant causative isolate (no duplicates) - The isolate must meet the
laboratory criteria of "significant pathogen" and be considered the "probable
causative agent" of a hospital or community acquired infection.

- Sources - All body sites are acceptable clinical sources for isolates to be included
in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage,
blood culture, wound smear). However, no more than 10 % of all isolates can come from
urine cultures.

- Within study group - Only isolates defined by the protocol are to be included.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Limited isolates from sources - No more than 10 % of all isolates from this study will
be derived from urine cultures.

- No banked or stored isolates.

- No duplicate isolates - Only one isolate per patient is permitted.

- Outside study group - Any isolate other than those defined by protocol.

NCT00488397
Pfizer
Completed
Tigecycline In-Vitro Surveillance Study In Taiwan

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title Tigecycline In-Vitro Surveillance Study In Taiwan
Official Title Tigecycline In-Vitro Surveillance Study In Taiwan
Brief Summary In-vitro surveillance study of tigecycline (Tygacil) in Taiwan.
Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population hospital or community acquired infection
Condition Community Acquired Infections
Intervention Other: In-vitro testing
This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
Study Groups/Cohorts 1
Intervention: Other: In-vitro testing
Publications * Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: March 11, 2011)
7902
Original Enrollment
 (submitted: June 18, 2007)
6000
Actual Study Completion Date February 2011
Actual Primary Completion Date February 2011   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Clinically relevant causative isolate (no duplicates) - The isolate must meet the laboratory criteria of "significant pathogen" and be considered the "probable causative agent" of a hospital or community acquired infection.
  • Sources - All body sites are acceptable clinical sources for isolates to be included in this study (Intra-abdominal infection, tracheal secretion/bronchoalveolar lavage, blood culture, wound smear). However, no more than 10 % of all isolates can come from urine cultures.
  • Within study group - Only isolates defined by the protocol are to be included.

Exclusion Criteria:

  • Limited isolates from sources - No more than 10 % of all isolates from this study will be derived from urine cultures.
  • No banked or stored isolates.
  • No duplicate isolates - Only one isolate per patient is permitted.
  • Outside study group - Any isolate other than those defined by protocol.
Sex/Gender
Sexes Eligible for Study: All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries China
Removed Location Countries Taiwan
 
Administrative Information
NCT Number NCT00488397
Other Study ID Numbers 3074A1-102091
B1811055 ( Other Identifier: Pfizer )
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Director, Clinical Trial Disclosure Group, Pfizer, Inc
Study Sponsor Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators Not Provided
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date March 2011

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now